Provided is a selenium-containing isoxazolamine compound having a structure as represented by formula I. Experiments show that the compound can effectively inhibit the TNF-α activity and adjust ferroptotic cell death. Also provided is a preparation method for the inhibitor and an application thereof in the preparation of drugs for preventing and treating TNF-α- and ferroptotic cell death-mediated diseases.